UY39135A - ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) - Google Patents
ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)Info
- Publication number
- UY39135A UY39135A UY0001039135A UY39135A UY39135A UY 39135 A UY39135 A UY 39135A UY 0001039135 A UY0001039135 A UY 0001039135A UY 39135 A UY39135 A UY 39135A UY 39135 A UY39135 A UY 39135A
- Authority
- UY
- Uruguay
- Prior art keywords
- cov
- sars
- monoclonal antibodies
- human monoclonal
- acute respiratory
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente divulgación se refiere a anticuerpos que se unen a y neutralizan el coronavirus denominado SARS-CoV-2 y a métodos de uso de los mismos.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063000299P | 2020-03-26 | 2020-03-26 | |
US202063002896P | 2020-03-31 | 2020-03-31 | |
US202063003716P | 2020-04-01 | 2020-04-01 | |
US202063023545P | 2020-05-12 | 2020-05-12 | |
US202063024204P | 2020-05-13 | 2020-05-13 | |
US202063024248P | 2020-05-13 | 2020-05-13 | |
US202063027173P | 2020-05-19 | 2020-05-19 | |
US202063037984P | 2020-06-11 | 2020-06-11 | |
US202063040224P | 2020-06-17 | 2020-06-17 | |
US202063040246P | 2020-06-17 | 2020-06-17 | |
US202163142196P | 2021-01-27 | 2021-01-27 | |
US202163161890P | 2021-03-16 | 2021-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39135A true UY39135A (es) | 2021-10-29 |
Family
ID=75540042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039135A UY39135A (es) | 2020-03-26 | 2021-03-25 | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) |
Country Status (29)
Country | Link |
---|---|
US (2) | US11345741B2 (es) |
EP (2) | EP4356924A3 (es) |
JP (1) | JP2023518849A (es) |
KR (1) | KR20220158053A (es) |
CN (1) | CN115768790A (es) |
AU (1) | AU2021242306A1 (es) |
BR (1) | BR112022018949A2 (es) |
CA (1) | CA3175110A1 (es) |
CL (1) | CL2022002594A1 (es) |
CO (1) | CO2022014820A2 (es) |
CR (1) | CR20220545A (es) |
DK (1) | DK4045533T3 (es) |
DO (1) | DOP2022000199A (es) |
EC (1) | ECSP22083269A (es) |
ES (1) | ES2973425T3 (es) |
FI (1) | FI4045533T3 (es) |
HR (1) | HRP20240182T1 (es) |
HU (1) | HUE065039T2 (es) |
IL (1) | IL296537A (es) |
LT (1) | LT4045533T (es) |
MX (1) | MX2022011892A (es) |
PE (1) | PE20230415A1 (es) |
PL (1) | PL4045533T3 (es) |
PT (1) | PT4045533T (es) |
RS (1) | RS65199B1 (es) |
SI (1) | SI4045533T1 (es) |
TW (1) | TW202200610A (es) |
UY (1) | UY39135A (es) |
WO (1) | WO2021195418A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL297700A (en) | 2020-04-27 | 2022-12-01 | Twist Bioscience Corp | Variable libraries of nucleic acids for the coronavirus |
EP4182687A2 (en) * | 2020-07-20 | 2023-05-24 | Bio-Rad Laboratories, Inc. | Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor |
WO2022034044A1 (en) * | 2020-08-10 | 2022-02-17 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
WO2022082217A1 (en) | 2020-10-16 | 2022-04-21 | Eureka Therapeutics, Inc. | Compositions for preventing or treating viral and other microbial infections |
TW202342095A (zh) * | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | 用於治療和預防covid—19之組成物 |
CN116802496A (zh) * | 2021-12-14 | 2023-09-22 | 杭州安旭生物科技股份有限公司 | 一种可结合SARS-CoV-2病毒的中和抗体及其应用 |
TW202342510A (zh) | 2022-02-18 | 2023-11-01 | 英商Rq生物科技有限公司 | 抗體 |
WO2023209177A1 (en) * | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
CN114870061A (zh) * | 2022-05-31 | 2022-08-09 | 康码(上海)生物科技有限公司 | 一种基于病毒阻断剂的空气喷雾剂及其用途 |
WO2024019110A1 (ja) * | 2022-07-20 | 2024-01-25 | 国立感染症研究所長が代表する日本国 | SARS-CoV-2に対する抗体 |
CN115925934A (zh) * | 2022-07-26 | 2023-04-07 | 北京昌平实验室 | 一种稳定性提高的人源化单克隆抗体及其应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
US5141648A (en) | 1987-12-02 | 1992-08-25 | Neorx Corporation | Methods for isolating compounds using cleavable linker bound matrices |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
WO1996016673A1 (en) | 1994-12-02 | 1996-06-06 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
US7666400B2 (en) | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
US7550143B2 (en) | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
SE520605C2 (sv) | 2001-06-29 | 2003-07-29 | Flir Systems Ab | Optiskt system innefattande en detektor och en bländare med decentreringsfunktion |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
AU2006232920B2 (en) | 2005-04-06 | 2011-09-29 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
US20110159001A1 (en) * | 2008-01-17 | 2011-06-30 | Institute For Research In Biomedicine | CROSS-NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES TO SARS-CoV AND METHODS OF USE THEREOF |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP4100434A1 (en) * | 2020-02-03 | 2022-12-14 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
HRP20231031T1 (hr) * | 2020-02-26 | 2023-12-22 | Vir Biotechnology, Inc. | Protutijela protiv sars-cov-2 |
US11053304B1 (en) * | 2020-03-23 | 2021-07-06 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 6nb6 |
-
2021
- 2021-03-25 FI FIEP21719462.0T patent/FI4045533T3/fi active
- 2021-03-25 AU AU2021242306A patent/AU2021242306A1/en active Pending
- 2021-03-25 UY UY0001039135A patent/UY39135A/es unknown
- 2021-03-25 PE PE2022002090A patent/PE20230415A1/es unknown
- 2021-03-25 WO PCT/US2021/024215 patent/WO2021195418A1/en active Application Filing
- 2021-03-25 LT LTEPPCT/US2021/024215T patent/LT4045533T/lt unknown
- 2021-03-25 TW TW110110951A patent/TW202200610A/zh unknown
- 2021-03-25 CA CA3175110A patent/CA3175110A1/en active Pending
- 2021-03-25 PT PT217194620T patent/PT4045533T/pt unknown
- 2021-03-25 HU HUE21719462A patent/HUE065039T2/hu unknown
- 2021-03-25 IL IL296537A patent/IL296537A/en unknown
- 2021-03-25 EP EP23209693.3A patent/EP4356924A3/en active Pending
- 2021-03-25 SI SI202130109T patent/SI4045533T1/sl unknown
- 2021-03-25 HR HRP20240182TT patent/HRP20240182T1/hr unknown
- 2021-03-25 BR BR112022018949A patent/BR112022018949A2/pt unknown
- 2021-03-25 ES ES21719462T patent/ES2973425T3/es active Active
- 2021-03-25 RS RS20240202A patent/RS65199B1/sr unknown
- 2021-03-25 CN CN202180023056.7A patent/CN115768790A/zh active Pending
- 2021-03-25 CR CR20220545A patent/CR20220545A/es unknown
- 2021-03-25 DK DK21719462.0T patent/DK4045533T3/da active
- 2021-03-25 US US17/212,949 patent/US11345741B2/en active Active
- 2021-03-25 KR KR1020227036951A patent/KR20220158053A/ko active Search and Examination
- 2021-03-25 JP JP2022557735A patent/JP2023518849A/ja active Pending
- 2021-03-25 MX MX2022011892A patent/MX2022011892A/es unknown
- 2021-03-25 EP EP21719462.0A patent/EP4045533B1/en active Active
- 2021-03-25 PL PL21719462.0T patent/PL4045533T3/pl unknown
-
2022
- 2022-03-18 US US17/655,503 patent/US20220281958A1/en active Pending
- 2022-09-21 DO DO2022000199A patent/DOP2022000199A/es unknown
- 2022-09-23 CL CL2022002594A patent/CL2022002594A1/es unknown
- 2022-10-19 CO CONC2022/0014820A patent/CO2022014820A2/es unknown
- 2022-10-26 EC ECSENADI202283269A patent/ECSP22083269A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2022002594A1 (es) | 2023-06-02 |
HRP20240182T1 (hr) | 2024-04-26 |
PT4045533T (pt) | 2024-02-14 |
IL296537A (en) | 2022-11-01 |
FI4045533T3 (fi) | 2024-02-02 |
EP4356924A3 (en) | 2024-06-12 |
PE20230415A1 (es) | 2023-03-07 |
CA3175110A1 (en) | 2021-09-30 |
US20220281958A1 (en) | 2022-09-08 |
ECSP22083269A (es) | 2022-11-30 |
SI4045533T1 (sl) | 2024-03-29 |
BR112022018949A2 (pt) | 2022-11-08 |
AU2021242306A1 (en) | 2022-11-17 |
US20210300999A1 (en) | 2021-09-30 |
CO2022014820A2 (es) | 2022-10-21 |
HUE065039T2 (hu) | 2024-04-28 |
PL4045533T3 (pl) | 2024-04-15 |
LT4045533T (lt) | 2024-02-26 |
DOP2022000199A (es) | 2022-11-30 |
JP2023518849A (ja) | 2023-05-08 |
TW202200610A (zh) | 2022-01-01 |
CR20220545A (es) | 2023-01-09 |
KR20220158053A (ko) | 2022-11-29 |
ES2973425T3 (es) | 2024-06-20 |
CN115768790A (zh) | 2023-03-07 |
EP4045533B1 (en) | 2023-11-15 |
DK4045533T3 (da) | 2024-02-12 |
EP4045533A1 (en) | 2022-08-24 |
WO2021195418A1 (en) | 2021-09-30 |
US11345741B2 (en) | 2022-05-31 |
MX2022011892A (es) | 2022-10-18 |
RS65199B1 (sr) | 2024-03-29 |
EP4356924A2 (en) | 2024-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39135A (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
CO2019010943A2 (es) | Anticuerpos de unión a vista a ph ácido | |
CL2020002410A1 (es) | Anticuerpos de unión a vista a ph ácido | |
CL2020002342A1 (es) | Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada | |
CL2020002539A1 (es) | Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos | |
CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
ECSP21052194A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
CL2021000258A1 (es) | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
BR112021004316A2 (pt) | Anticorpos de agonistas anti-trem-2 | |
CO2021000046A2 (es) | Anticuerpos de unión a vista a ph ácido | |
CL2023000701A1 (es) | Anticuerpos que se unen a il1rap y usos de los mismos | |
CO2021015254A2 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
CL2023000741A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos. | |
UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
CO2023008643A2 (es) | Anticuerpos anti-hla-g y uso de estos | |
AR121370A1 (es) | Anticuerpos anti-cd19 humano | |
BR112023017728A2 (pt) | Anticorpos anti-nectin-4 e uso dos mesmos | |
CO2022010204A2 (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
CL2022002833A1 (es) | Anticuerpos anti-flt3 y composiciones | |
DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
BR112021024176A2 (pt) | Anticorpos anti-angpt2 | |
CO2023016777A2 (es) | Anticuerpos anti-tmprss6 y sus usos | |
CO2024001850A2 (es) | Caracterización de anticuerpos monoclonales potentes y ampliamente neutralizantes contra el sars-cov-2, sus variantes y los coronavirus relacionados y métodos de uso |